1. FRI0088 SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY. (June 2019) Authors: Edwards, Christopher; Chyrok, Veronica; Monnet, Joëlle; Ullmann, Martin; Vlachos, Pantelis Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 707 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗